SCHEMBL24179865

SCHEMBL24179865

Cc1ccc(OCC2COC(Cn3cncn3)(c3ccc(Cl)cc3Cl)O2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 19/20 0.75
LMNA P02545 3/20 0.75
CYP51A1 Q16850 3/20 0.75
FYN P06241 2/20 0.75
NR1I2 O75469 2/20 0.75
HSP90AA1 P07900 2/20 0.75
CHRM2 P08172 2/20 0.75
ADRA2A P08913 2/20 0.75
TSHR P16473 2/20 0.75
ADRA2B P18089 2/20 0.75
SLC6A2 P23975 2/20 0.75
HTR2A P28223 2/20 0.75
SLC6A4 P31645 2/20 0.75
SLC6A3 Q01959 2/20 0.75
KCNH2 Q12809 2/20 0.75
PGR P06401 1/20 0.75
CHRM4 P08173 1/20 0.75
CHRM5 P08912 1/20 0.75
CHRM1 P11229 1/20 0.75
ADRA2C P18825 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16975620 1.00 CYP3A4 (0.75) CYP3A4LMNACYP51A1FYNNR1I2
SCHEMBL15927829 0.94 CYP3A4 (0.84) CYP3A4LMNACYP51A1FYNNR1I2
SCHEMBL10498436 0.94 CYP3A4 (0.84) CYP3A4LMNACYP51A1FYNNR1I2
SCHEMBL20710072 0.94 CYP3A4 (0.67) CYP3A4LMNACYP51A1FYNNR1I2
SCHEMBL23467326 0.94 CYP3A4 (0.67) CYP3A4LMNACYP51A1FYNNR1I2
SCHEMBL11272056 0.91 CYP3A4 (0.72) CYP3A4LMNACYP51A1FYNNR1I2
SCHEMBL11381040 0.91 CYP3A4 (0.72) CYP3A4LMNACYP51A1FYNNR1I2
SCHEMBL11272424 0.91 CYP3A4 (0.73) CYP3A4LMNACYP51A1FYNNR1I2
SCHEMBL11268895 0.90 CYP3A4 (0.70) CYP3A4LMNACYP51A1FYNNR1I2
SCHEMBL11270079 0.90 CYP3A4 (0.70) CYP3A4LMNACYP51A1FYNNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11220493-B2 Compositions and methods for the treatment of fungal infections CELLIX BIO PRIVATE LIMITED (IN) 2022-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11220493-B2 Compositions and methods for the treatment of fungal infections SI, CYP3A7, ERG28 CYP3A4 4/4885LMNA 2173/4885CYP51A1 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.